Leerink reiterates Eli Lilly stock rating on gene therapy progress

Leerink reiterates Eli Lilly stock rating on gene therapy progress

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.